Literature DB >> 21188541

Epithelioid glioblastoma changed to typical glioblastoma: the methylation status of MGMT promoter and 5-ALA fluorescence.

Shingo Tanaka1, Mitsutoshi Nakada, Yutaka Hayashi, Satoko Nakada, Seiko Sawada-Kitamura, Natsuki Furuyama, Tomohide Suzuki, Tomoya Kamide, Yasuhiko Hayashi, Seiji Yano, Jun-ichiro Hamada.   

Abstract

A 55-year-old man was admitted to our hospital complaining of left hemiparesis. Magnetic resonance imaging (MRI) showed a smooth ring-like enhanced cystic tumor in the right parietal lobe. He underwent gross total resection of the tumor under neuronavigation and 5-aminolevulinic acid (5-ALA) fluorescence guiding method. Histopathological examination of the tumor showed small cells formed epithelioid solid nests with some focus of duct-like structure. On the basis of the MRI and operative and histological findings, this tumor was diagnosed as a metastatic poorly differentiated carcinoma, although the primary cancer could not be detected by metastatic work-ups. Afterward, this tumor recurred repeatedly. Histopathological examination of specimen from the fourth surgery indicated that the tumor was a glioblastoma (GBM). In the review of the histology and immunohistochemistry of the first tumor, atypical fibrillary cells were seen between solid nests and positive for glial fibrillary acidic protein, therefore the tumor was retrospectively diagnosed as epithelioid GBM. We assessed whether the changes in histopathology were accompanied by changes in the methylation status of O6-methylguanine methyltransferase (MGMT) promoter and the status of 5-ALA fluorescence. The methylation status of the MGMT promoter was found to have changed from methylated to unmethylated and 5-ALA fluorescence became positive along with the histological change.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21188541     DOI: 10.1007/s10014-010-0009-x

Source DB:  PubMed          Journal:  Brain Tumor Pathol        ISSN: 1433-7398            Impact factor:   3.298


  7 in total

1.  BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation.

Authors:  Bette K Kleinschmidt-DeMasters; Dara L Aisner; Nicholas K Foreman
Journal:  Am J Surg Pathol       Date:  2015-04       Impact factor: 6.394

2.  Epithelioid GBMs show a high percentage of BRAF V600E mutation.

Authors:  Bette Kay Kleinschmidt-DeMasters; Dara L Aisner; Diane K Birks; Nicholas K Foreman
Journal:  Am J Surg Pathol       Date:  2013-05       Impact factor: 6.394

Review 3.  Various shades of red-a systematic analysis of qualitative estimation of ALA-derived fluorescence in neurosurgery.

Authors:  Marcel A Kamp; Zarela Krause Molle; Christopher Munoz-Bendix; Marion Rapp; Michael Sabel; Hans-Jakob Steiger; Jan F Cornelius
Journal:  Neurosurg Rev       Date:  2016-05-25       Impact factor: 3.042

Review 4.  Changes of O6-Methylguanine DNA Methyltransferase (MGMT) Promoter Methylation in Glioblastoma Relapse-A Meta-Analysis Type Literature Review.

Authors:  Jonas Feldheim; Almuth F Kessler; Camelia M Monoranu; Ralf-Ingo Ernestus; Mario Löhr; Carsten Hagemann
Journal:  Cancers (Basel)       Date:  2019-11-21       Impact factor: 6.639

5.  Patterns of regulatory activity across diverse human cell types predict tissue identity, transcription factor binding, and long-range interactions.

Authors:  Nathan C Sheffield; Robert E Thurman; Lingyun Song; Alexias Safi; John A Stamatoyannopoulos; Boris Lenhard; Gregory E Crawford; Terrence S Furey
Journal:  Genome Res       Date:  2013-03-12       Impact factor: 9.043

6.  Composite pleomorphic xanthoastrocytoma-epithelioid glioneuronal tumor with BRAF V600E mutation - report of three cases.

Authors:  Dara L Aisner; Kathy L Newell; Ania G Pollack; Bette K Kleinschmidt-Demasters; Gary K Steinberg; Lawrence T Smyth; Hannes Vogel
Journal:  Clin Neuropathol       Date:  2014 Mar-Apr       Impact factor: 1.368

7.  BRAF V600E mutation and BRAF VE1 immunoexpression profiles in different types of glioblastoma.

Authors:  Zeynep Tosuner; Melin Özgün Geçer; Mustafa Aziz Hatiboğlu; Anas Abdallah; Seval Turna
Journal:  Oncol Lett       Date:  2018-06-06       Impact factor: 2.967

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.